Ashburn, VA – September 5, 2018 – Aperiomics, a company that helps doctors and their patients worldwide solve difficult medical cases, limit the use of antibiotics, and drastically cut trial-and-error testing, has been named a semifinalist “Startup of the Year” by the national Consumer Technology Association (CTA).
The most recent accolade is part of CTA’s “Innovate Celebrate,” billed as “the premiere global conference bridging the gap between the very best emerging startups and the world’s leading technology brands.” Winners will be named at the 6th Annual Innovate Celebrate event in Boston October 15-17. More than 500 qualifying, emerging founders representing 38 countries and numerous industries that range from artificial intelligence and e-commerce to healthtech and more, were judged by dozens of industry leaders.
Last year Aperiomics was recognized as one of the DC region’s most innovative companies as a finalist in The Greater Washington Innovation Awards. The company was named “Life Sciences Innovator of the Year” in 2016.
Aperiomics is the only company of its kind and scope in the world. Its proprietary technology can identify every bacteria, DNA virus, fungi and parasite – the causes of infections — in a single test. It does this using a method called “deep shotgun metagenomic sequencing” of the DNA in any sample (patient, environmental, etc.).
Company CEO Dr. Crystal Icenhour, an expert in infectious disease, said, “We’re very excited to be among all of the great companies to tell our story at Innovate Celebrate. It will give us higher visibility among doctors and their patients who can benefit the most from the amazing work our team does.”
Aperiomics is the only company identifying every bacteria, DNA virus, fungi and parasite in one test. Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot. The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test through deep metagenomic shotgun sequencing of the DNA in any sample, be it patient, environmental, or otherwise. The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens. This breakthrough, only possible through Aperiomics, can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about our successes in helping others. Aperiomics is supported by the National Science Foundation. It was named Life Sciences Innovator of the Year in 2016 and a finalist in the 2018 Greater Washington Innovation Awards. For more information, visit www.aperiomics.com or call (703) 229-0406.